Evidence map›Paper›PMID 32026389›Full record

ArticlePulmonary therapy2018

Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis.

Bernardino Alcázar Navarrete, Isabelle Boucot, Ian Naya, Lee Tombs, David A Lipson, Chris Compton, Ana R Sousa, Gregory Feldman

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02799784 (A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol With Tiotropium/Olodaterol Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02799784 phase4completednot on this map

A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol With Tiotropium/Olodaterol Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

TypeinterventionalSponsorGlaxoSmithKlineRan2016 to 2017Enrolled236ConditionsPulmonary Disease, Chronic ObstructiveArmsUMEC/VI, TIO/OLO, Albuterol/salbutamol
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.International journal of chronic obstructive pulmonary disease · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Bernardino Alcázar NavarreteNeumología, Hospital de Alta Resolución de Loja, Granada, Spain. balcazarnavarrete@gmail.com.
Isabelle BoucotGlobal Respiratory Franchise, GSK, Brentford, Middlesex, UK.
Ian NayaGlobal Respiratory Franchise, GSK, Brentford, Middlesex, UK.
Lee TombsPrecise Approach Ltd, Contingent Worker on Assignment at GSK, Stockley Park West, Uxbridge, Middlesex, UK.
David A LipsonRespiratory Research and Development, GSK, Collegeville, PA, USA.
Chris ComptonGlobal Respiratory Franchise, GSK, Brentford, Middlesex, UK.
Ana R SousaDiscovery Medicine, GSK, Stockley Park West, Uxbridge, Middlesex, UK.
Gregory FeldmanSouth Carolina Pharmaceutical Research, Spartanburg, SC, USA.
GlaxoSmithKline (United States) · USHospital Comarcal de Inca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAppropriate timing for dual bronchodilator therapy initiation in chronic obstructive pulmonary disease (COPD) management is uncertain. Combination therapy is recommended as step-up from monotherapy or first-line treatment in patients with persistent symptoms. In this setting, umeclidinium/vilanterol (UMEC/VI) demonstrated improved lung function and reduced rescue medication use over tiotropium/olodaterol (TIO/OLO). This subgroup analysis explored efficacy differences between these combinations in patients naïve to COPD maintenance therapy before study entry.

methodsPost hoc analysis of an 8-week, randomized, open-label, assessor-blind, two-period crossover study (204990; NCT02799784) comparing UMEC/VI 62.5/25 mcg and TIO/OLO 5/5 mcg, focused on maintenance-naïve (MN) patients with moderate COPD and persistent symptoms (modified Medical Research Council dyspnea score ≥ 2). Change from baseline (CFB) in trough forced expiratory volume in 1 s (FEV

resultsThe MN population comprised 63% of the intent-to-treat (ITT) population (148/236 patients) and had similar baseline demographics. At week 8, adjusted mean (standard error) improvements in trough FEV

conclusionsThese results highlight that the efficacy difference between UMEC/VI and TIO/OLO demonstrated in the ITT population is maintained in MN patients. Greater lung function improvements with UMEC/VI versus TIO/OLO were accompanied by symptom improvements, as reflected in a significantly lower need for supplemental rescue medication.

fundingGSK.

trial registrationNCT02799784.

Indexed as

COPDLABALAMALong-acting muscarinic antagonistLong-acting β2-agonistMaintenance-naïveOlodaterolTiotropiumUmeclidiniumVilanterol

Identifiers

PMID32026389
PMCPMC6967227
OpenAlexW2808699155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.